ImmunoGen, Inc. Reports on Additions to Its Industry-Leading ADC Technology Portfolio at ImmunoGen, Inc.-National Cancer Institute-EORTC Conference
Published: Oct 23, 2013
ImmunoGen, Inc. (Nasdaq: IMGN) today reported on additions to the Company’s portfolio of antibody-drug conjugate (ADC) technologies at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting being held in Boston, MA.1,2,3 Of particular interest were presentations on the Company’s new platform of DNA-acting payload agents ImmunoGen has created to further extend the opportunity for ADC cancer treatments.
Help employers find you! Check out all the jobs and post your resume.